Stock Analysis
Surgical Innovations Group (LON:SUN) Full Year 2023 Results
Key Financial Results
- Revenue: UK£12.0m (up 5.9% from FY 2022).
- Net loss: UK£509.0k (down by 293% from UK£264.0k profit in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Surgical Innovations Group shares are up 11% from a week ago.
Risk Analysis
Be aware that Surgical Innovations Group is showing 2 warning signs in our investment analysis and 1 of those is potentially serious...
Valuation is complex, but we're helping make it simple.
Find out whether Surgical Innovations Group is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About AIM:SUN
Surgical Innovations Group
Surgical Innovations Group plc, together with its subsidiaries, designs, develops, manufactures, and sells devices for use in minimally invasive surgery and precision engineering markets in the United Kingdom, Europe, the Asia Pacific, the United States, and internationally.
Excellent balance sheet and good value.
